The approval relies on positive data from the POTOMAC Phase III trial.
In the POTOMAC trial, one year of Imfinzi plus BCG reduced disease recurrence, progression or death risk by 32%. Credit: Sai Thaw Kyar / Shutterstock.com.
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC).
This marks the first approved immunotherapy combination for this patient segment in the US. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
